{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:49:40Z","timestamp":1772754580742,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2009,3,17]],"date-time":"2009-03-17T00:00:00Z","timestamp":1237248000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1007\/s10067-009-1149-4","type":"journal-article","created":{"date-parts":[[2009,3,16]],"date-time":"2009-03-16T09:16:22Z","timestamp":1237194982000},"page":"787-791","source":"Crossref","is-referenced-by-count":69,"title":["Use of tumor necrosis factor-\u03b1 (TNF-\u03b1) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients"],"prefix":"10.1007","volume":"28","author":[{"given":"Sophia","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Primal P.","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Berney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,3,17]]},"reference":[{"issue":"1","key":"1149_CR1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.23177","volume":"58","author":"CG Helmick","year":"2008","unstructured":"Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, Pillemer SR, Reveille JD, Stone JH, National Arthritis Data Workgroup (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum 58(1):15\u201325","journal-title":"Arthritis Rheum"},{"key":"1149_CR2","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra032906","volume":"350","author":"NJ Olsen","year":"2004","unstructured":"Olsen NJ, Stein CM (2004) New drugs for rheumatoid arthritis. N Engl J Med 350:2167\u20132179","journal-title":"N Engl J Med"},{"key":"1149_CR3","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMct055183","volume":"355","author":"DL Scott","year":"2006","unstructured":"Scott DL, Kingsley GH (2006) Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 355:704\u2013712","journal-title":"N Engl J Med"},{"key":"1149_CR4","first-page":"363","volume":"18","author":"MY Mok","year":"2000","unstructured":"Mok MY, Ng WL, Yuen MF, Wong RW, Lau CS (2000) Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 18:363\u2013368","journal-title":"Clin Exp Rheumatol"},{"key":"1149_CR5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-2249.1998.00469.x","volume":"111","author":"B Kallinowski","year":"1998","unstructured":"Kallinowski B, Haseroth K, Marinos G, Hanck C, Stremmel W, Theilmann L, Singer MV, Rossol S (1998) Induction of tumor necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 111:269\u2013277","journal-title":"Clin Exp Immunol"},{"key":"1149_CR6","first-page":"1372","volume":"9","author":"F Monsalve-DeCastillo","year":"2002","unstructured":"Monsalve-DeCastillo F, Romero TA, Estevez J, Costa LL, Atencio R, Porto L, Callejas D (2002) Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases. Clin Diagn Lab Immunol 9:1372\u20131375","journal-title":"Clin Diagn Lab Immunol"},{"key":"1149_CR7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0168-8278(99)80060-9","volume":"30","author":"H Zylberberg","year":"1999","unstructured":"Zylberberg H, Rimaniol AC, Pol S, Masson A, D Groote D, Berthelot P, Bach JF, Brechot C, Zavala F (1999) Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 30:185\u2013191","journal-title":"J Hepatol"},{"key":"1149_CR8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2004.028209","volume":"63","author":"LH Calabrese","year":"2004","unstructured":"Calabrese LH, Zein N, Vassilopoulos D (2004) Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B and HIV infection. Ann Rheum Dis 63:18\u201324","journal-title":"Ann Rheum Dis"},{"key":"1149_CR9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10067-006-0394-z","volume":"26","author":"S Aslanidis","year":"2007","unstructured":"Aslanidis S, Vassiliadis T, Pyrpasopoulou A, Douloumpakas I, Zamboulis C (2007) Inhibition of TNF-\u03b1 does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 26:261\u2013264","journal-title":"Clin Rheumatol"},{"key":"1149_CR10","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2007.10.011","volume":"38","author":"MB Carroll","year":"2008","unstructured":"Carroll MB, Bond MI (2008) Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 38:208\u2013217","journal-title":"Semin Arthritis Rheum"},{"key":"1149_CR11","first-page":"1624","volume":"30","author":"M Michel","year":"2003","unstructured":"Michel M, Duvoux C, Hezode C, Cherqui D (2003) Fulminant hepatitis after Infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol 30:1624\u20131625","journal-title":"J Rheumatol"},{"key":"1149_CR12","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3748\/wjg.v12.i6.974","volume":"12","author":"G Millonig","year":"2006","unstructured":"Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W (2006) Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 12:974\u2013976","journal-title":"World J Gastroenterol"},{"key":"1149_CR13","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.20702","volume":"51","author":"FA Parke","year":"2004","unstructured":"Parke FA, Reveille JD (2004) Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 51:800\u2013804","journal-title":"Arthritis Rheum"},{"key":"1149_CR14","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/ard.62.11.1078","volume":"62","author":"JR Peterson","year":"2003","unstructured":"Peterson JR, Hsu FC, Simkin PA, Wener MH (2003) Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 62:1078\u20131082","journal-title":"Ann Rheum Dis"},{"key":"1149_CR15","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/rheumatology\/kel123","volume":"45","author":"CH Roux","year":"2006","unstructured":"Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L (2006) Safety of anti-TNF-\u03b1 therapy in rheumatoid arthritis and spondyloarthropathies with concurrent B or C chronic hepatitis. Rheumatology 45:1294\u20131297","journal-title":"Rheumatology"},{"key":"1149_CR16","first-page":"1944","volume":"35","author":"C Ferri","year":"2008","unstructured":"Ferri C, Ferraccioli G, Ferrari D, Galeazzi M, Lapadula G, Montecucco C, Triolo G, Valentini G, Valesini G (2008) Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 35:1944\u20131949","journal-title":"J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-009-1149-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-009-1149-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-009-1149-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:51:35Z","timestamp":1559119895000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-009-1149-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,17]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["1149"],"URL":"https:\/\/doi.org\/10.1007\/s10067-009-1149-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,17]]}}}